MIR100HG Regulates CALD1 Gene Expression by Targeting miR-142-5p to Affect the Progression of Bladder Cancer Cells in vitro, as Revealed by Transcriptome Sequencing

Zhang, Sheng; Wang, Qin; Li, Wenfeng; Chen, Jinzhong

doi:10.3389/fmolb.2021.793493

Cited by 12 publications

(19 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ying W et al found that MIR100HG is lowly expressed in BC, and the overexpression of MIR100HG inhibits the proliferation and invasion of BC cells (Ying et al, 2021). Conversely, it had been reported from Zhang S's study that the overexpression of MIR100HG effectively promoted the proliferation, migration, and invasion of BC cells, and it was proved to be an independent prognostic factor for BC (Zhang et al, 2021). Our results suggested that MIR100HG was lowly expressed in PCa and indicated that this lncRNA might play a tumor-suppressive role in PCa.…”

Section: Discussioncontrasting

confidence: 52%

A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer

Ren

Yang²,

Wang³

et al. 2023

Front. Genet.

View full text Add to dashboard Cite

Background: As a new form of regulated cell death, cuproptosis differs profoundly from apoptosis, ferroptosis, pyroptosis, and necroptosis. The correlation between cuproptosis and long non-coding RNAs (lncRNAs) has been increasingly studied recently. In this study, a novel cuproptosis-related lncRNA prognostic signature was developed to investigate biochemical recurrence (BCR) and tumor immune landscape in prostate cancer (PCa).Methods and Materials: The transcriptome data and clinicopathologic information of PCa patients were downloaded from The Cancer Genome Atlas (TCGA). Pearson’s correlation analysis was applied to identify lncRNAs associated with cuproptosis. Based on Cox regression analysis and the least absolute shrinkage and selection operator (LASSO) regression analysis, we developed a cuproptosis-related lncRNA prognostic model (risk score) to predict the BCR of PCa patients. Additionally, we also constructed a nomogram with the risk score and clinicopathologic features. The biological function, tumor mutation burden (TMB), immune cell infiltration, expression levels of immune checkpoint genes, and anti-cancer drug sensitivity were investigated.Results: We constructed and validated the cuproptosis-related lncRNA signature prognostic model (risk score) by six crlncRNAs. All patients were divided into the low- and high-risk groups based on the median risk score. The Kaplan–Meier (KM) survival analysis revealed that the high-risk group had shorter BCR-free survival (BCRFS). The risk score has been proven to be an independent prognostic factor of BCR in PCa patients. In addition, a nomogram of risk scores and clinicopathologic features was established and demonstrated an excellent predictive capability of BCR. The ROC curves further validated that this nomogram had higher accuracy of predicting the BCR compared to other clinicopathologic features. We also found that the high-risk group had higher TMB levels and more infiltrated immune cells. Furthermore, patients with high TMB in the high-risk group were inclined to have the shortest BCRFS. Finally, patients in the high-risk group were more susceptible to docetaxel, gefitinib, methotrexate, paclitaxel, and vinblastine.Conclusion: The novel crlncRNA signature prognostic model shows a greatly prognostic prediction value of BCR for PCa patients, extends our thought on the association of cuproptosis and PCa, and provides novel insights into individual-based treatment strategies for PCa.

show abstract

Section: Discussioncontrasting

confidence: 52%

A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer

Ren

Yang²,

Wang³

et al. 2023

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…Wang et al (48) conducted a comprehensive analysis of mRNA, lncRNAs, and miRNAs between MIBC and non-tumor bladder samples based on the TCGA database and found that MIR100HG was significantly differentially expressed between MIBC and normal samples and was downregulated in MIBC. On the contrary, Zhang et al (49) found that MIR100HG was significantly up-regulated in BC tissues in comparison to adjacent tissues, and its high expression was positively correlated with the histological grade and clinical stage of BC. Besides, the expression of MIR100HG was negatively related to the OS of patients (50).…”

Section: Bladder Cancermentioning

confidence: 89%

“…Additionally, overexpression of MIR100HG inhibits tumor formation in nude mice in vivo. However, Zhang et al (49) found that high expression of MIR100HG significantly enhanced the proliferation, migration, and invasion abilities of BC cells. Taken together, these findings suggested that MIR100HG may play a vital role in BC and more studies should be replicated for the controversial results to validate the specificity and sensitivity of the MIR100HG product or individual MIR100HG as biomarkers.…”

Section: Bladder Cancermentioning

confidence: 98%

See 1 more Smart Citation

LncmiRHG-MIR100HG: A new budding star in cancer

Wang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

MIR100HG, also known as lncRNA mir-100-let-7a-2-mir-125b-1 cluster host gene, is a new and critical regulator in cancers in recent years. MIR100HG is dysregulated in various cancers and plays an oncogenic or tumor-suppressive role, which participates in many tumor cell biology processes and cancer-related pathways. The errant expression of MIR100HG has inspired people to investigate the function of MIR100HG and its diagnostic and therapeutic potential in cancers. Many studies have indicated that dysregulated expression of MIR100HG is markedly correlated with poor prognosis and clinicopathological features. In this review, we will highlight the characteristics and introduce the role of MIR100HG in different cancers, and summarize the molecular mechanism, pathways, chemoresistance, and current research progress of MIR100HG in cancers. Furthermore, some open questions in this rapidly advancing field are proposed. These updates clarify our understanding of MIR100HG in cancers, which may pave the way for the application of MIR100HG-targeting approaches in future cancer diagnosis, prognosis, and therapy.

show abstract

“…MIR100HG inhibits the expression of miR-142-5p, which targets CALD1, thus relieving CALD1 from this inhibitory effect. Consequently, upregulated CALD1 results in the induction of aggressive features in bladder cancer cells[ 55 ].…”

Section: Role Of Cad In Other Cancer Typesmentioning

confidence: 99%

Emerging role of caldesmon in cancer: A potential biomarker for colorectal cancer and other cancers

Alnuaimi¹,

Nair²,

Malhab³

et al. 2022

WJGO

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a devastating disease, mainly because of metastasis. As a result, there is a need to better understand the molecular basis of invasion and metastasis and to identify new biomarkers and therapeutic targets to aid in managing these tumors. The actin cytoskeleton and actin-binding proteins are known to play an important role in the process of cancer metastasis because they control and execute essential steps in cell motility and contractility as well as cell division. Caldesmon (CaD) is an actin-binding protein encoded by the CALD1 gene as multiple transcripts that mainly encode two protein isoforms: High-molecular-weight CaD, expressed in smooth muscle, and low-molecular weight CaD (l-CaD), expressed in nonsmooth muscle cells. According to our comprehensive review of the literature, CaD, particularly l-CaD, plays a key role in the development, metastasis, and resistance to chemoradiotherapy in colorectal, breast, and urinary bladder cancers and gliomas, among other malignancies. CaD is involved in many aspects of the carcinogenic hallmarks, including epithelial mesenchymal transition via transforming growth factor-beta signaling, angiogenesis, resistance to hormonal therapy, and immune evasion. Recent data show that CaD is expressed in tumor cells as well as in stromal cells, such as cancer-associated fibroblasts, where it modulates the tumor microenvironment to favor the tumor. Interestingly, CaD undergoes selective tumor-specific splicing, and the resulting isoforms are generally not expressed in normal tissues, making these transcripts ideal targets for drug design. In this review, we will analyze these features of CaD with a focus on CRC and show how the currently available data qualify CaD as a potential candidate for targeted therapy in addition to its role in the diagnosis and prognosis of cancer.

show abstract

MIR100HG Regulates CALD1 Gene Expression by Targeting miR-142-5p to Affect the Progression of Bladder Cancer Cells in vitro, as Revealed by Transcriptome Sequencing

Cited by 12 publications

References 41 publications

A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer

A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer

LncmiRHG-MIR100HG: A new budding star in cancer

Emerging role of caldesmon in cancer: A potential biomarker for colorectal cancer and other cancers

Contact Info

Product

Resources

About